A Phase 3 interventional study of mRNA-1345 in Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 44 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases — none open to participants now, none under way, none of them phase 3. mRNA-1345 respiratory syncytial virus vaccine · Virus Diseases.
Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, this one is the 4th largest by enrollment, is one of 4 that started in 2023, is one of 4 in phase 3, and was the 7th registered.
656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.
Browse Virus Diseases studies →None of the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases is open now. The open studies under Virus Diseases, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5
First in 2020; this study’s year is marked. 4 started in 2023.
This study's enrollment of 1,153 is above the median of 100 across 464 interventional studies indexed under Virus Diseases.
Median enrollment 579 across the 10 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
47 studies in Virus Diseases by Moderna, Inc.: 2 open now, 6 under way, 1 of them phase 3. Of 40 finished, 17 (43%) have results posted.
Among the 47 studies in Virus Diseases by Moderna, Inc., this one is the 15th largest by enrollment of the 37 interventional ones that give a count, is one of 14 that started in 2023, is one of 11 in phase 3, and was the 34th registered.
Moderna, Inc.’s Virus Diseases studies by the year they started, since 2019.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, from their registry updates:
Among Moderna, Inc.’s 47 in Virus Diseases:
This tab as a report to print or save as PDF → With an account.
The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to \<60 years.
Part B of the study will evaluate the safety and immune response to mRNA-1345 in adults who received solid organ transplant (SOT).
Key Inclusion Criteria:
Part A:
Documented confirmation by a physician of the diagnosis of at least one of the following conditions:
Part B:
Parts A and B:
- Able to comply with study requirements.
Key Exclusion Criteria:
Part A:
Part B:
Note: Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single injection of mRNA-1345 administered intramuscularly (IM) on Day 1.
Biological: mRNA-1345
Single injection of mRNA-1345 administered IM on Day 1.
Biological: mRNA-1345
Two injections of mRNA-1345 administered IM on Day 1 and Day 57.
Biological: mRNA-1345
Sterile liquid for injection
Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
Time frame: Day 1 through Day 7 (7 days post injection) for Part A and Day 1 through Day 64 (7 days post second injection) for Part B
Number of Participants with Unsolicited Adverse Events (AEs)
Time frame: Day 1 through Day 28 (28 days post injection) for Part A and Day 1 through Day 84 (28 days post second injection) for Part B
Number of Participants With Medically Attended AEs (MAAEs)
Time frame: Day 1 through Month 6 (for Part A) and Day 1 through Month 9 (for Part B)
Number of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and AEs Leading to Discontinuation
Time frame: Day 1 through End of Study (Day 730)
Part A: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (Abs) at Day 29
Time frame: Day 29
Part B: GMT of Serum RSV-A and RSV-B Neutralizing Abs at Day 85
Time frame: Day 85
Part A: Seroresponse Rate (SRR) of RSV-A and RSV-B Neutralizing Abs on Day 29
Time frame: Day 29
Part A: Geometric Mean Concentration (GMC) of Serum RSV Prefusion Conformation of the F Protein (Pre-F) Binding Abs
Time frame: Up to End of Study (Day 730)
Part A: Geometric Mean Fold-Rise (GMFR) of Serum RSV Pre-F Binding Abs
Time frame: Up to End of Study (Day 730)
Part A: SRR of Serum RSV Pre-F Binding Abs at Postbaseline/Baseline Levels
Time frame: Baseline up to Day 730
Part A: Number of Participants with ≥2-Fold Increase in RSV Pre-F Binding Abs
Time frame: Up to End of Study (Day 730)
Part A: GMT of Serum RSV-A and RSV-B Neutralizing Abs at Day 29
Time frame: Day 29
Part A: GMT of Postinjection/Baseline Titers to RSV-A and RSV-B Neutralizing Abs
Time frame: Baseline up to Day 730
Part A: GMFR of Postinjection/Baseline Titers to RSV-A and RSV-B Neutralizing Abs
Time frame: Baseline up to Day 730
Part A: SRR of Serum RSV-A and RSV-B Neutralizing Abs
Time frame: Up to End of Study (Day 730)
Part A: Number of Participants with ≥2-Fold Increase in RSV-A and RSV-B Neutralizing Abs Titers
Time frame: Up to End of Study (Day 730)
Part B: GMT of Serum RSV-A and RSV-B Neutralizing Abs at Day 29
Time frame: Day 29
Part B: SRR of Serum RSV-A and RSV-B Neutralizing Abs on Day 29
Time frame: Day 29
Part B: SRR of Serum RSV-A and RSV-B Neutralizing Abs on Day 85
Time frame: Day 85
Part B: GMT of Serum RSV-A and RSV-B Neutralizing Abs
Time frame: Up to End of Study (Day 730)
Part B: GMFR of Serum RSV-A and RSV-B Neutralizing Abs
Time frame: Up to End of Study (Day 730)
Part B: SRR of Serum RSV-A and RSV-B Neutralizing Abs at Postbaseline/Baseline Levels
Time frame: Baseline up to Day 730
Part B: Number of Participants with ≥2-Fold Increase in RSV-A and RSV-B Neutralizing Abs
Time frame: Up to End of Study (Day 730)
Part B: GMC of Serum RSV Pre-F Binding Abs
Time frame: Up to End of Study (Day 730)
Part B: GMFR of Serum RSV Pre-F Binding Abs
Time frame: Up to End of Study (Day 730)
Part B: SRR of Serum RSV Pre-F Binding Abs at Postbaseline/Baseline Levels
Time frame: Baseline up to End of Study (Day 730)
Part B: Number of Participants with ≥2-Fold Increase in RSV Pre-F Binding Abs
Time frame: Up to End of Study (Day 730)
Ran from Oct 2023 to primary completion in Jul 2026, 33 months.
Of 40 industry-sponsored phase 3 interventional studies under Virus Diseases, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 24. This study's 33 months is above that.
Counting every sponsor, half of 57 studies reached it within 14 months; a quarter within 8 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA-1345 respiratory syncytial virus vaccine